7rec: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='7rec' size='340' side='right'caption='[[7rec]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='7rec' size='340' side='right'caption='[[7rec]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[7rec]] is a 7 chain structure with sequence from [https://en.wikipedia.org/wiki/ | <table><tr><td colspan='2'>[[7rec]] is a 7 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7REC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7REC FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=7ZV:5-HYDROXYDICLOFENAC'>7ZV</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rec FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rec OCA], [https://pdbe.org/7rec PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rec RCSB], [https://www.ebi.ac.uk/pdbsum/7rec PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rec ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rec FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rec OCA], [https://pdbe.org/7rec PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rec RCSB], [https://www.ebi.ac.uk/pdbsum/7rec PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rec ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[https://www.uniprot.org/uniprot/KCC2A_HUMAN KCC2A_HUMAN] CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity (By similarity). | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 7rec" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 7rec" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Calcium/calmodulin dependent protein kinase 3D structures|Calcium/calmodulin dependent protein kinase 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Chi | [[Category: Chi CC]] | ||
[[Category: Gee | [[Category: Gee CL]] | ||
[[Category: Kuriyan | [[Category: Kuriyan J]] | ||
[[Category: McSpadden | [[Category: McSpadden ED]] | ||
Latest revision as of 19:29, 18 October 2023
Structure of Thr354Asn, Glu355Gln, Thr412Asn, Ile414Met, Ile464His, and Phe467Met mutant human CaMKII alpha hub bound to 5-HDCStructure of Thr354Asn, Glu355Gln, Thr412Asn, Ile414Met, Ile464His, and Phe467Met mutant human CaMKII alpha hub bound to 5-HDC
Structural highlights
FunctionKCC2A_HUMAN CaM-kinase II (CAMK2) is a prominent kinase in the central nervous system that may function in long-term potentiation and neurotransmitter release. Member of the NMDAR signaling complex in excitatory synapses it may regulate NMDAR-dependent potentiation of the AMPAR and synaptic plasticity (By similarity). Publication Abstract from PubMedCa(2+)/calmodulin-dependent protein kinase II alpha subunit (CaMKIIalpha) is a key neuronal signaling protein and an emerging drug target. The central hub domain regulates the activity of CaMKIIalpha by organizing the holoenzyme complex into functional oligomers, yet pharmacological modulation of the hub domain has never been demonstrated. Here, using a combination of photoaffinity labeling and chemical proteomics, we show that compounds related to the natural substance gamma-hydroxybutyrate (GHB) bind selectively to CaMKIIalpha. By means of a 2.2-A x-ray crystal structure of ligand-bound CaMKIIalpha hub, we reveal the molecular details of the binding site deep within the hub. Furthermore, we show that binding of GHB and related analogs to this site promotes concentration-dependent increases in hub thermal stability believed to alter holoenzyme functionality. Selectively under states of pathological CaMKIIalpha activation, hub ligands provide a significant and sustained neuroprotection, which is both time and dose dependent. This is demonstrated in neurons exposed to excitotoxicity and in a mouse model of cerebral ischemia with the selective GHB analog, HOCPCA (3-hydroxycyclopent-1-enecarboxylic acid). Together, our results indicate a hitherto unknown mechanism for neuroprotection by a highly specific and unforeseen interaction between the CaMKIIalpha hub domain and small molecule brain-penetrant GHB analogs. This establishes GHB analogs as powerful tools for investigating CaMKII neuropharmacology in general and as potential therapeutic compounds for cerebral ischemia in particular. GHB analogs confer neuroprotection through specific interaction with the CaMKIIalpha hub domain.,Leurs U, Klein AB, McSpadden ED, Griem-Krey N, Solbak SMO, Houlton J, Villumsen IS, Vogensen SB, Hamborg L, Gauger SJ, Palmelund LB, Larsen ASG, Shehata MA, Kelstrup CD, Olsen JV, Bach A, Burnie RO, Kerr DS, Gowing EK, Teurlings SMW, Chi CC, Gee CL, Frolund B, Kornum BR, van Woerden GM, Clausen RP, Kuriyan J, Clarkson AN, Wellendorph P Proc Natl Acad Sci U S A. 2021 Aug 3;118(31). pii: 2108079118. doi:, 10.1073/pnas.2108079118. PMID:34330837[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||